Madrigal Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2016-01-01
- Employees
- 276
- Market Cap
- $5.5B
- Introduction
Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Ch...
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal Function
- First Posted Date
- 2024-05-03
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Madrigal Pharmaceuticals, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT06397872
- Locations
- 🇺🇸
Madrigal Research Center, Chicago, Illinois, United States
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
- First Posted Date
- 2022-08-15
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- Madrigal Pharmaceuticals, Inc.
- Target Recruit Count
- 700
- Registration Number
- NCT05500222
- Locations
- 🇺🇸
Covenant Research - Fort Myers, Fort Myers, Florida, United States
🇺🇸Gastrointestinal Specialists of Georgia, Marietta, Georgia, United States
🇺🇸The Liver Institute at Methodist Dallas Medical Center, Dallas, Texas, United States
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
- First Posted Date
- 2021-07-06
- Last Posted Date
- 2023-12-04
- Lead Sponsor
- Madrigal Pharmaceuticals, Inc.
- Target Recruit Count
- 1000
- Registration Number
- NCT04951219
- Locations
- 🇺🇸
Miami Dade Medical Research Institute, Miami, Florida, United States
🇺🇸Platinum - Sterling Research Group - Springdale, Cincinnati, Ohio, United States
🇺🇸Texas Liver Institute/American Research Corporation, San Antonio, Texas, United States
Drug Interaction Study of MGL-3196 With Clopidogrel
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2020-12-28
- Lead Sponsor
- Madrigal Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT04671069
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
Drug Interaction Study of MGL-3196 With Pioglitazone
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Madrigal Pharmaceuticals, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT04671056
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects
- Conditions
- Interventions
- First Posted Date
- 2020-11-25
- Last Posted Date
- 2023-10-05
- Lead Sponsor
- Madrigal Pharmaceuticals, Inc.
- Target Recruit Count
- 87
- Registration Number
- NCT04643795
- Locations
- 🇺🇸
Madrigal Research Center, San Antonio, Texas, United States
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients
- Conditions
- Interventions
- First Posted Date
- 2019-12-13
- Last Posted Date
- 2023-09-05
- Lead Sponsor
- Madrigal Pharmaceuticals, Inc.
- Target Recruit Count
- 1343
- Registration Number
- NCT04197479
- Locations
- 🇺🇸
Northwestern Memorial Physicians Group, Chicago, Illinois, United States
🇺🇸Floridian Clinical Research, Hialeah, Florida, United States
🇺🇸Dallas Research Center, Dallas, Texas, United States
A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
- Conditions
- Interventions
- First Posted Date
- 2019-04-03
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Madrigal Pharmaceuticals, Inc.
- Target Recruit Count
- 1759
- Registration Number
- NCT03900429
- Locations
- 🇨🇦
Toronto Liver Center, Toronto, Ontario, Canada
🇺🇸Florida Research Institute, Lakewood Ranch, Florida, United States
🇺🇸GI Specialists of Georgia, Marietta, Georgia, United States
Bioavailability Study of MGL-3196 Tablets Compared to Capsules
- First Posted Date
- 2018-01-29
- Last Posted Date
- 2019-09-18
- Lead Sponsor
- Madrigal Pharmaceuticals, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT03413124
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
Radiolabeled Study to Determine the Mass Balance of [14C] MGL-3196
- First Posted Date
- 2017-07-18
- Last Posted Date
- 2017-12-19
- Lead Sponsor
- Madrigal Pharmaceuticals, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT03220165
- Locations
- 🇺🇸
Worldwide Clinical Trials Early Phase Services, LLC, San Antonio, Texas, United States